Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Sci Signal. 2015 Oct 6;8(397):ra98. doi: 10.1126/scisignal.aac5418

Fig. 3. Verteporfin decreases cell growth in patient-derived enteroid and xenograft models.

Fig. 3

(A and B) Representative images of (A) adenoma or (B) adenocarcinoma patient-derived enteroids treated with verteporfin (VP) for the indicated doses and times. (C and D) Immunofluorescence staining and quantification (% positive staining ± S.E.M, n=3 enteroids of Ki67 and cleaved caspase3 in patient-derived (C) adenoma or (D) adenocarcinoma enteroids in the presence of vehicle (Veh) or VP for 6 days. (E to H) Size (E), weight (F), H&E staining (G), and proliferative and apoptotic analysis (H) of CRC patient-derived xenografts in mice treated with vehicle (n=6) or VP (n=8). Data are mean ± S.E.M of at least three independent experiments. *p < 0.05; **p<0.01; ***p<0.001 vs Veh. Scale bars, 50μm.